Business
SPECTRAL DIAGNOSTICS REFILES THIRD QUARTER UNAUDITED INTERIM FINANCIAL STATEMENTS
Apr. 11, 2011 (Canada NewsWire Group) -- TORONTO, April 11 /CNW/ - Spectral Diagnostics Inc....
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n Apr. 11, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTORONTO, April 11 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI), a Phase III company developing the first theranostic treatment for\n severe sepsis and septic shock, today announced that it has refiled, on\n SEDAR, its unaudited interim financial statements for the nine month\n period ended September 30, 2010 to include specific disclosure that\n these interim financial statements have not been subject to a review by\n the Company's auditors. Other than this disclosure, there are no\n changes to these unaudited interim financial statements.\n\n\nAbout Spectral Diagnostics\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment for severe sepsis and septic\n shock. Toraymyxin is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared\n diagnostic for the risk of developing sepsis, Spectral's EUPHRATES\n trial is the world's first theranostics trial in the area of sepsis.\n\n\nToraymyxin has been approved for therapeutic use in 18 countries, and\n has been used safely and effectively in more than 80,000 patients to\n date. In March, 2009, Spectral obtained the exclusive development and\n commercial rights in the U.S. for Toraymyxin, and in November, 2010,\n signed an exclusive distribution agreement for ...